Tue Jun 15 2021

Measuring suPAR in COVID-19 patients presents a valuable tool for improving risk stratification accuracy and helping to predict the risk of developing severe consequences of a COVID-19 infection.

supar predicts covid

Lippi and coworkers recently published a letter in Clinical Chemistry and Laboratory Medicine confirming their findings. They reviewed multiple studies on suPAR levels in COVID-19 patients, revealing that suPAR values significantly increased in critically ill patients compared to those with milder symptoms. Specifically, suPAR levels were 55% higher in patients with severe forms of illness.

The analysis indicates that suPAR measurement can significantly enhance risk stratification in COVID-19 patients, aiding in predicting severe outcomes like acute kidney injury (AKI) and thrombosis.

Furthermore, high suPAR concentrations link to increased oxidative stress in kidney cells, potentially worsening kidney damage caused directly by SARS-CoV-2 and indirectly by microthrombi. This increase in suPAR may also block plasmin production by inhibiting urokinase-type plasminogen activator (uPA), leading to a state of hypofibrinolysis. This condition, part of the hypercoagulable state seen in severe COVID-19 cases, can intensify the risk and severity of thrombosis.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates